Overexpression of other cancer-immunity cycle markers were also observed including myeloid suppression markers (e.g. CCL2, CCR2 and CSF1R; 10-22%), metabolic immune escape markers (e.g. ADORA2A and IDO1; 9-16%) and T-cell primed markers (e.g. CD40, GITR, ICOS and OX40; 4-26%). This evidence concerns the gene TNFRSF18 and cancer.